JOP20190209A1 - مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان - Google Patents

مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان

Info

Publication number
JOP20190209A1
JOP20190209A1 JOP/2019/0209A JOP20190209A JOP20190209A1 JO P20190209 A1 JOP20190209 A1 JO P20190209A1 JO P20190209 A JOP20190209 A JO P20190209A JO P20190209 A1 JOP20190209 A1 JO P20190209A1
Authority
JO
Jordan
Prior art keywords
compounds
quinolin
treating cancer
salts
imidazo
Prior art date
Application number
JOP/2019/0209A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of JOP20190209A1 publication Critical patent/JOP20190209A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

يتعلق الاختراع الحالي بصفة عامة بمركبات بالصيغة (I) صورة الصيغة (I) وأملاح مقبولة صيدلانياً منها، حيث R1 لها أي من المعاني المعرفة في هذه الوثيقة. يتعلق الوصف أيضاً باستخدام مركبات بالصيغة (I) وأملاح منها لعلاج أو الوقاية من مرض ناتج بواسطة ATM، بما في ذلك السرطان. يتعلق الوصف أيضاً بتركيبات صيدلانية تشتمل على مركبات إيميدازو [4، 5-c] كينولين -2- أون بها استبدال وأملاح مقبولة صيدلانياً منها؛ وأطقم تشتمل على تلك المركبات والأملاح.
JOP/2019/0209A 2017-03-16 2017-06-16 مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان JOP20190209A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472080P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
JOP20190209A1 true JOP20190209A1 (ar) 2019-09-12

Family

ID=61801891

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0209A JOP20190209A1 (ar) 2017-03-16 2017-06-16 مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان

Country Status (25)

Country Link
US (2) US20200087300A1 (ar)
EP (1) EP3596076A1 (ar)
JP (1) JP2020514344A (ar)
KR (1) KR20190129923A (ar)
CN (1) CN110431139B (ar)
AU (1) AU2018234985B2 (ar)
BR (1) BR112019018723A2 (ar)
CA (1) CA3055258A1 (ar)
CL (1) CL2019002527A1 (ar)
CO (1) CO2019010029A2 (ar)
CR (1) CR20190429A (ar)
DO (1) DOP2019000228A (ar)
EA (1) EA038233B1 (ar)
EC (1) ECSP19066134A (ar)
IL (1) IL269272A (ar)
JO (1) JOP20190209A1 (ar)
MA (1) MA49884A (ar)
MX (1) MX2019010898A (ar)
NI (1) NI201900094A (ar)
PE (1) PE20191486A1 (ar)
PH (1) PH12019502086A1 (ar)
SG (1) SG11201908065YA (ar)
TW (1) TW201843151A (ar)
UA (1) UA124554C2 (ar)
WO (1) WO2018167203A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV15575A (lv) 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
WO2021260580A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
JP2023542606A (ja) * 2020-09-21 2023-10-11 ウェイ ジョン 血液脳関門透過能力を有する置換１－（３，３－ジフルオロピペリジン－４－イル）－イミダゾ［４，５－ｃ］キノリン－２－オン化合物
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
BRPI1010621A2 (pt) * 2009-06-04 2016-06-21 Novartis Ag derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (ar) * 2014-05-08 2018-04-21
BR122019005502B1 (pt) * 2015-04-02 2024-02-27 Merck Patent Gmbh Compostos de imidazolonilquinolinas, seus usos, composições farmacêuticas, e kit
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Also Published As

Publication number Publication date
MA49884A (fr) 2020-06-24
CR20190429A (es) 2019-11-12
AU2018234985A1 (en) 2019-10-24
IL269272A (en) 2019-11-28
US20210347775A1 (en) 2021-11-11
CN110431139A (zh) 2019-11-08
EA038233B1 (ru) 2021-07-28
TW201843151A (zh) 2018-12-16
EP3596076A1 (en) 2020-01-22
SG11201908065YA (en) 2019-09-27
NI201900094A (es) 2020-03-18
PH12019502086A1 (en) 2020-03-09
MX2019010898A (es) 2019-11-07
BR112019018723A2 (pt) 2020-04-07
PE20191486A1 (es) 2019-10-18
UA124554C2 (uk) 2021-10-05
WO2018167203A1 (en) 2018-09-20
ECSP19066134A (es) 2019-09-30
CA3055258A1 (en) 2018-09-20
EA201992090A1 (ru) 2020-03-06
AU2018234985B2 (en) 2020-04-02
CL2019002527A1 (es) 2019-11-22
CN110431139B (zh) 2022-07-05
US20200087300A1 (en) 2020-03-19
CO2019010029A2 (es) 2019-09-30
DOP2019000228A (es) 2019-09-30
KR20190129923A (ko) 2019-11-20
JP2020514344A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
MX2020014098A (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington.
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
TN2016000511A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
MX2018011283A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020551493A1 (en) Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors